Deals this week: Savara, Tiziana Life Sciences, Verastem

3rd August 2018 (Last Updated August 12th, 2019 10:38)

Savara plans to raise $48.9m through an underwritten public offering of more than four million shares of its common stock priced at $11.5 a share.

Savara plans to raise $48.9m through an underwritten public offering of more than four million shares of its common stock priced at $11.5 a share.

The underwriters will have a 30-day option to buy an additional 0.63 million shares of the company’s common stock.

Based in the US, Savara is a clinical-stage pharmaceutical company focused on the development of novel drugs for the treatment of rare and life-threatening respiratory diseases.

The company plans to use the funds towards clinical development, working capital, and other general corporate purposes.

Wilson Sonsini Goodrich & Rosati has been appointed as the legal adviser to the company for the offering.

UK-based biotechnology company Tiziana Life Sciences has filed a registration statement with the US Securities and Exchange Commission (SEC) to raise $11.79m through an initial public offering of American Depositary Shares (ADS).

The underwriters will be granted a 30-day option to buy additional shares as part of the offering.

Laidlaw & Company (UK) has been appointed as the underwriter to the company for the offering.

The company plans to use the funds for clinical development activities, working capital, and general corporate purposes.

Verastem plans to issue securities through a public offering to raise $200m.

The company intends to issue the securities periodically in any combination of common stock, preferred stock, and warrants.

Based in the US, Verastem is a biopharmaceutical company engaged in the development and commercialisation of drugs for cancer treatment.

"Verastem plans to issue securities through a public offering to raise $200m."

The funds raised through the offering are intended to be used towards research and development (R&D), clinical trial expenditures, and working capital.

Ropes & Gray has been appointed as the legal adviser to the company for the offering.

Caladrius Biosciences plans to issue securities in a public offering to raise $150m.

The company intends to issue the securities periodically in any combination of common stock, preferred stock, and warrants.

Based in the US, Caladrius Biosciences is a clinical-stage biopharmaceutical company that develops therapies and regenerative medicines for cardiovascular diseases.

The funds raised through the offering are intended to be used towards research and development (R&D), business expansion, and other general corporate purposes.

Mintz Levin Cohn Ferris Glovsky and Popeo has been appointed as the legal adviser to the company for the offering.

Omniome has raised $60m through a series B funding round led by Decheng Capital and Hillhouse Capital Group.

The funding round also included participation from Lam Research Capital and Nan Fung Life Sciences and existing investors ARCH Venture Partners, Domain Associates and Altitude Life Science Ventures.

Based in the US, Omniome is a biotechnology company focused on the development of DNA sequencing platform.

The company plans to use the funds towards hiring new employees and accelerating the development of its sequencing by binding (SBB) platform.

ContraFect has raised $10m through an underwritten public offering of five million shares of its common stock priced at $2 a share.

The underwriters will have a 30-day option to buy an additional 0.75 million shares of the company’s common stock.

Based in the US, ContraFect is a biotechnology company that develops therapies for life-threatening diseases.

The company plans to use the funds towards clinical development, working capital, and other general corporate purposes.

Latham & Watkins has been appointed as the legal adviser to the company for the offering.